The keywords target multiple pathways that allow cancer cells to evade immune detection and programmed death. Overcoming these specific metabolic and regulatory blocks restores the body's natural ability to eliminate malignant cells.

Aberrant arginine methyltransferase activity drives pathological gene expression and cellular proliferation. Inhibiting this enzymatic overactivity halts tumor progression and overcomes resistance to standard chemotherapy.

Lack of predictive markers leads to suboptimal patient selection and poor clinical outcomes. Identifying specific biological indicators ensures therapy is targeted to those most likely to benefit.